Entrada Therapeutics procures $116m Series B
Entrada Therapeutics Inc., a biotechnology company focused on treating devastating diseases using intracellular biologics, has secured $116 million in Series B financing.
Entrada Therapeutics Inc., a biotechnology company focused on treating devastating diseases using intracellular biologics, has secured $116 million in Series B financing.
Copyright PEI Media
Not for publication, email or dissemination